Abstract

Hepatitis C virus (HCV), the etiological agent of the most common and dangerous diseases of the liver, is a major health problem worldwide. Despite many attempts, there is still no vaccine available. Although many drugs have been approved for use mostly in combination regimen, their high costs make them out of reach in less developed regions. Previously, we have synthesized a series of compounds belonging to uridine derivatives of 2-deoxy sugars and have proved that some of them possess antiviral activity against influenza A virus associated with N-glycosylation inhibition. Here, we analyze the antiviral properties of these compounds against HCV. Using cell culture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and replicon cell lines, we have shown high anti-HCV activity of two compounds. Our results indicated that compounds 2 and 4 significantly reduced HCVcc propagation with IC50 values in low μM range. Further experiments using the HCVpp system confirmed that both compounds significantly impaired the infectivity of produced HCVpp due to the inhibition of the correct maturation of viral glycoproteins. Overall, our results suggest that inhibiting the glycosylation process might be a good target for new therapeutics not only against HCV, but other important viral pathogens which contain envelopes with highly glycosylated proteins.

Highlights

  • Hepatitis C virus (HCV) belongs to the Hepacivirus genus in the Flaviviridae family

  • We have shown that uridine derivatives of 2‐deoxy sugars exert good anti‐classical

  • We have shown that uridine derivatives ofIn2-deoxy sugars exert good swine fever virus and anti‐influenza virus activity this study, we evaluated theanti-classical in vitro swineactivities fever virus andcompounds anti-influenza virus activity

Read more

Summary

Introduction

Hepatitis C virus (HCV) belongs to the Hepacivirus genus in the Flaviviridae family. It is a positive-stranded RNA virus which is the major cause of chronic liver diseases, like cirrhosis and liver carcinoma [1]. Until 2011, a combination of pegylated IFN alpha and ribavirin was used in the treatment of HCV-infected patients [2]. It was ineffective in at least 50% of cases and was associated with numerous side-effects. The most intensive research has been focused on chemically-modified nucleoside and nucleotide derivatives as effective anti-HCV agents [3,4]. A highly active drug, sofosbuvir, belonging to the nucleotide prodrugs, is one of the most successful examples [5,6]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call